Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check16 days agoChange DetectedThe webpage has updated its date references, adding new dates in April 2025 while removing older dates from February 2025.SummaryDifference0.3%
- Check23 days agoChange DetectedThe page has been updated to include new information about Medullary Thyroid Cancer and its associated study, while significant details regarding the study's purpose and eligibility criteria have been removed.SummaryDifference12%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 27, 2025.SummaryDifference0.2%
- Check38 days agoChange DetectedThe page has been updated to reflect a new version release, moving from v2.14.2 to v2.14.3, and the last update date has changed from February 27, 2025, to March 25, 2025.SummaryDifference0.2%
- Check67 days agoChange DetectedThe webpage has updated its date references to include new dates in February 2025, while older dates have been removed.SummaryDifference1.0%
Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.